{"schema_version":"secwatch.filing_event.v1","accession":"0001129928-26-000072","form_type":"8-K","ticker":"ONCY","cik":"0001129928","company_name":"ONCOLYTICS BIOTECH INC","filed_at":"2026-10-14T13:33:28+00:00","discovered_at":"2026-10-14T13:34:00.246755+00:00","generated_at":"2026-10-14T13:34:06.875398+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Oncolytics sees final PanCAN grant payment this quarter; GOBLET Cohort 4 data due Q4 2026","bullets":["Oncolytics (Nasdaq: ONCY) expects the final Pancreatic Cancer Action Network grant payment later this quarter after completing Cohort 5 wind-down activities.","Final Cohort 4 results, testing pelareorep with atezolizumab in second-line or later squamous cell anal carcinoma, are expected in Q4 2026.","Initial Cohort 5 results in first-line metastatic pancreatic ductal adenocarcinoma are expected in H1 2027, but could slip as patients stay on treatment.","CMO Thomas Heineman said Cohort 4 median overall survival exceeds the company's expectations, with the full data set still being processed.","Oncolytics said every GOBLET cohort that enrolled the required number of patients met its pre-specified efficacy success criteria."],"urls":{"canonical":"https://secwatch.observer/filing/0001129928-26-000072","json":"https://secwatch.observer/filing/0001129928-26-000072.json","markdown":"https://secwatch.observer/filing/0001129928-26-000072.md","text":"https://secwatch.observer/filing/0001129928-26-000072.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000072/0001129928-26-000072-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000072/oncy-20261014.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-14T13:34:06.875398+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}